Company Biomind Labs Inc.

Equities

BMND.F

CA0907021012

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-03 pm EDT			5-day change	1st Jan Change
0.11 ^USD	0.00%		0.00%	+10.00%

2023	Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	CI
2023	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Biomind Labs Inc. is a Canada-based biotech research and development company. The Company is primarily engaged in biotech platform that integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production with special focus on scientific research, clinical trials and in jurisdictions that open a fast track in the molecule to market lifecycle. Through its acceleration platform, it is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline for treating a range of therapeutic indications. 5-MeO-DMT is a powerful psychedelic tryptamine. Under the 5-MeO-DMT Program, the Company is focused on two drug candidates: BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and BMND08: 5-MeO-DMT novel formulation indicated for Alzheimerâs disease. Mescaline is a psychedelic alkaloid of the phenethylamine class. DMT Program is a serotonergic psychedelic.

Number of employees: 5

Managers	Title	Age	Since
Alejandro Antalich CEO	Chief Executive Officer	-	-
Oscar Leon DFI	Director of Finance/CFO	-	-
Fernando Ferreira CTO	Chief Tech/Sci/R&D Officer	-	-
Paola Díaz Dellavalle CTO	Chief Tech/Sci/R&D Officer	-	-
Martin Daners LAW	General Counsel	-	-
Juan Presa LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Ravi Sood CHM	Chairman	48	-
Fraser Buchan BRD	Director/Board Member	40	-
Oscar Leon DFI	Director of Finance/CFO	-	-
Alejandro Antalich CEO	Chief Executive Officer	-	-
Ben Illigens BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	74,761,853	45,014,839 ( 60.21 %)	0	60.21 %

Name	Equities	%	Valuation
Union Group International Holdings Ltd. 39.79 %	29,747,014	39.79 %	7 M $
All-Canadian Management, Inc. 3.739 %	2,795,182	3.739 %	642 892 $
Ravi Sood 0.000000 %	0	0.000000 %	- $
Fraser Buchan 0.000000 %	0	0.000000 %	- $
Oscar Leon 0.000000 %	0	0.000000 %	- $
Alejandro Antalich 0.000000 %	0	0.000000 %	- $
Ben Illigens 0.000000 %	0	0.000000 %	- $

Biomind Labs, Inc.

Building Ceibo Office 002 Camino Saravia

, Pando

http://biomindlabs.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOMIND LABS INC.	+10.00%	8.22M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research